Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HAI FUDR and Dexamethasone Combined With Systemic Gemcitabine and Oxaliplatin in Unresectable Intrahepatic Cholangiocarcinoma
NCT01862315Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- May 2013
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of floxuridine, dexamethasone, gemcitabine and oxaliplatin in intrahepatic cholangiocarcinoma (ICC) (3 arms), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoints: Progression Free Survival at 6 months and Response at 6 months. Started May 2013; status: completed.
02
Drugs
floxuridinedexamethasonegemcitabineoxaliplatin
03
Conditions
intrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on NCT01862315.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01862315.